Pfizer Discontinues A Phase 3 Study Of Figitumumab
Pfizer Inc. announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).
Original Source of Pfizer Discontinues A Phase 3 Study Of Figitumumab
